LINDSEY NIELSEN: Open Payments
NPI 1639865967 · MODESTO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$519 in 27 payments from 9 companies in 2025. Trend: 2023 $23 · 2024 $132 · 2025 $519
Food & beverage: $519
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 9 | $145 |
| Neurocrine BioSciences, Inc. | 3 | $80 |
| Axsome Therapeutics, Inc. | 3 | $64 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $63 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $61 |
| Otsuka America Pharmaceutical, Inc. | 2 | $35 |
| Supernus Pharmaceuticals, Inc. | 2 | $33 |
| Teva Pharmaceuticals USA, Inc. | 1 | $21 |
| E.R. Squibb & Sons, L.L.C. | 1 | $16 |
Products named: VRAYLAR, INGREZZA, Auvelity, CAPLYTA, TRINTELLIX, REXULTI, Qelbree, AUSTEDO XR.
Industry payments across CA — which companies pay providers there.
